Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Of all the companies mentioned in the report, is Bioheart well advanced in clinical s than the others with regards to heart?
It was a horrible report
From the latest 10-Q
Basis and business presentation
Bioheart, Inc. (the “Company”) was incorporated under the laws of the State of Florida in August, 1999. The Company is in the development stage, as defined by Accounting Standards Codification subtopic 915-10, Development Stage Entities (“ASC 915-10”) and is the cardiovascular sector of the cell technology industry delivering cell therapies and biologics that help address congestive heart failure, lower limb ischemia, chronic heart ischemia, acute myocardial infarctions and other issues. To date, the Company has not generated significant sales revenues, has incurred expenses, and has sustained losses. Consequently, its operations are subject to all the risks inherent in the establishment of a new business enterprise. For the period from inception through September 30, 2013, the Company has accumulated a deficit through its development stage of $117,453,724
Great video, but no mention of the bio company
Let's go down the road of Bioheart being aquired by another company. What happens to the stock we own?
I came across this article, competition
http://singularityhub.com/2013/10/25/healing-damaged-hearts-with-stem-cell-implants-gets-new-technique/
Same here.
Universities are building heart centers all over the USA doing the same sort of work as Bioheart. The competition is heating up!
My money is on eminent positive news and the stock is rock solid entry, pick up shares folks.
Taking a dive, news may not be good here folks.
Is this the competition? i don't see BHRT mentioned in the article.
Came across this, hope where not in a free fall.
http://www.macroaxis.com/invest/ratio/BHRT.OB--Probability_Of_Bankruptcy
218.06 185.42 181.76 155.97 133.15
Diluted shares rose from 133.15 on 06.30.12 to 218.06 on 06.30.13
https://www.google.com/finance?q=OTCMKTS%3ABHRT&fstype=ii&ei=pnInUrC6EYKelQOjUA
Has anyone written to any of the officers about the company's strategy to bring down debt?
I don't expect any catalyst news that would cause the stock to skyrocket until trials are well out of phase 3 and product to market. Until then, enjoy the roller coaster ride the shorts have us on.
Good find, thanks.
Old news
What would a buy out do to our shares?
wow, zero volume, really?
One thing that troubles me is that there hasn't been any insider buying since February of 2012.
what's the chance or risk BHRT will take our monies and run.
I picked up 140K last week or so, adding more when price point drops more.
Last insider buy was last year, Feb 5th? Any recent insider buys?
Feb 5, 2012 HART CHARLES ADirector 3,571,430 Direct Purchase at $0.01 per share. 35,714
Jan 29, 2012 AHN SAMUEL SDirector 5,500,000 Direct Purchase at $0.02 per share. 110,000
Nov 30, 2011 AHN SAMUEL SDirector 1,084,200 Direct Purchase at $0.05 per share. 54,210
Nov 7, 2011 AHN SAMUEL SDirector 2,500,000 Direct Purchase at $0.04 per share. 100,000
Jul 28, 2011 MURPHY WILLIAM P JRDirector 1,666,670 Indirect Purchase at $0.06 per share. 100,000
months
Bhrt does not appear on the FDA calander.
http://www.biopharmcatalyst.com/fda-calendar/